menu
    • menu

    Company profile for Arrowhead Pharmaceuticals

    NEW Drugs in Dev: 37
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, th...
    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Arrowhead PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    225 South Lake Avenue, Suite 1050 Pasadena, CA 91101
    Telephone
    Telephone
    626-304-3400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://arrowheadpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Asia Pharma Expo

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arrowhead Pharma Reveals Q1 2026 Financial Report
    Arrowhead Pharma Reveals Q1 2026 Financial Report

    05 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260205875637/en/Arrowhead-Pharmaceuticals-Reports-Fiscal-2026-First-Quarter-Results

    BUSINESSWIRE
    05 Feb 2026
    Share Share
    Arrowhead Pharma Starts Phase 1/2A Trial For ARO-DIMER-PA
    Arrowhead Pharma Starts Phase 1/2A Trial For ARO-DIMER-PA

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    Arrowhead Pharma To Webcast Q1 Fiscal 2026 Results
    Arrowhead Pharma To Webcast Q1 Fiscal 2026 Results

    20 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260120458782/en/Arrowhead-Pharmaceuticals-to-Webcast-Fiscal-2026-First-Quarter-Results

    BUSINESSWIRE
    20 Jan 2026
    Share Share
    Arrowhead Pharma Gets NMPA Nod For REDEMPLO In China For FCS
    Arrowhead Pharma Gets NMPA Nod For REDEMPLO In China For FCS

    07 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260107019764/en/Arrowhead-Pharmaceuticals-Announces-NMPA-Approval-of-REDEMPLO-plozasiran-for-Familial-Chylomicronemia-Syndrome-FCS-in-China

    BUSINESSWIRE
    07 Jan 2026
    Share Share
    Arrowhead Pharma Reports Weight Loss in Obesity RNAi Trial
    Arrowhead Pharma Reports Weight Loss in Obesity RNAi Trial

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106676011/en/Arrowhead-Pharmaceuticals-Announces-Interim-Clinical-Data-on-RNAi-based-Obesity-Candidates-Showing-Weight-Loss-in-Obese-Patients-with-Diabetes-and-Improved-Measures-of-Body-Composition

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Health Canada Approves Arrowhead's REDEMPLO for Adult FCS
    Health Canada Approves Arrowhead's REDEMPLO for Adult FCS

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105004282/en/Arrowhead-Pharmaceuticals-Announces-Health-Canada-Approval-of-REDEMPLO-plozasiran-to-Reduce-Triglycerides-in-Adults-with-Familial-Chylomicronemia-Syndrome-FCS

    BUSINESSWIRE
    05 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search